Literature DB >> 20229039

Esomeprazole-induced rhabdomyolysis in a patient with heart failure.

Uwe Tröger, Ines Reiche, Marilene S Jepsen, Christof Huth, Stefanie M Bode-Böger.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20229039     DOI: 10.1007/s00134-010-1854-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  7 in total

Review 1.  Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

Authors:  David W J Clark; Johanna Strandell
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

2.  Ocular damage associated with proton pump inhibitors.

Authors:  P S Schönhöfer; B Werner; U Tröger
Journal:  BMJ       Date:  1997-06-21

3.  Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis.

Authors:  T S Mikkelsen; P Toft
Journal:  Acta Anaesthesiol Scand       Date:  2005-07       Impact factor: 2.105

4.  Autoimmune syndrome induced by omeprazole.

Authors:  K Sivakumar; M C Dalakas
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

5.  Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.

Authors:  Clive H Wilder-Smith; Patrik Bondarov; Marie Lundgren; Mohammad Niazi; Kerstin Röhss; Henrik Ahlbom; Lars Nyman
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

Review 6.  When should stress ulcer prophylaxis be used in the ICU?

Authors:  Jean-Pierre Quenot; Nadiejda Thiery; Saber Barbar
Journal:  Curr Opin Crit Care       Date:  2009-04       Impact factor: 3.687

Review 7.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

  7 in total
  6 in total

1.  Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Authors:  Alice Capogrosso Sansone; Irma Convertino; Maria Teresa Galiulo; Stefano Salvadori; Stefania Pieroni; Tamara Knezevic; Stefania Mantarro; Alessandra Marino; Manfred Hauben; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

2.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

Review 3.  Proton Pump Inhibitors and Risk of Rhabdomyolysis.

Authors:  Scott J Duncan; Colin W Howden
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

4.  Omeprazole-associated rhabdomyolysis.

Authors:  Kumiko Tanaka; Taka-Aki Nakada; Ryuzo Abe; Sakae Itoga; Fumio Nomura; Shigeto Oda
Journal:  Crit Care       Date:  2014-07-24       Impact factor: 9.097

5.  Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report.

Authors:  Dae-Hong Jeon; Yire Kim; Min Jeong Kim; Hyun Seop Cho; Eun Jin Bae; Se-Ho Chang; Dong Jun Park
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 6.  Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.

Authors:  Yoshikazu Kinoshita; Norihisa Ishimura; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.